ROCHESTER GENERAL HOSPITAL
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1847-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
10
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Prevalence of Humoral Dysfunction in Pts With Frequent Exacerbations of COPD, and the Effect of SCIgR for Prevention
- Conditions
- COPD Exacerbation Acute
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Rochester General Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05764993
- Locations
- 🇺🇸
Rochester Regional Health Ctr for Clinical Research - Alexander Park, Rochester, New York, United States
🇺🇸Rochester Regional Health - Ctr for Clinical Research - Linden Oaks, Rochester, New York, United States
🇺🇸Rochester Regional Health - Ctr for Clinical Research - Greece, Rochester, New York, United States
Dynamic Change and Immune Response to Nasopharyngeal Carriage and Acute Otitis Media Pathogens
- Conditions
- Acute Otitis Media
- First Posted Date
- 2021-06-30
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Rochester General Hospital
- Target Recruit Count
- 320
- Registration Number
- NCT04946084
- Locations
- 🇺🇸
Rochester General Hospital, Rochester, New York, United States
Humoral Immunodeficiency in CLL and Therapy With Subcutaneous Ig
- First Posted Date
- 2018-11-05
- Last Posted Date
- 2020-08-26
- Lead Sponsor
- Rochester General Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT03730129
- Locations
- 🇺🇸
Allergy, Immunology, Rheumatology at Rochester Regional Health, Rochester, New York, United States
Dupilumab for Aspirin-exacerbated Respiratory Disease
- First Posted Date
- 2018-07-23
- Last Posted Date
- 2020-08-26
- Lead Sponsor
- Rochester General Hospital
- Target Recruit Count
- 11
- Registration Number
- NCT03595488
- Locations
- 🇺🇸
Rochester Regional Health - Allergy/Immunology, Rochester, New York, United States
Humoral Immunodeficiency With Rituximab and Therapy With Subcutaneous Ig
- Conditions
- Secondary Immune Deficiency
- Interventions
- Drug: 20% subcutaneous immunoglobulin
- First Posted Date
- 2017-07-07
- Last Posted Date
- 2021-04-19
- Lead Sponsor
- Rochester General Hospital
- Target Recruit Count
- 16
- Registration Number
- NCT03211065
- Locations
- 🇺🇸
Allergy and Immunology, 222 Alexander Street, Rochester, New York, United States
- Prev
- 1
- 2
- Next
News
Rochester General Hospital Pioneers U.S. Trial of AquaPass for Heart Failure
Rochester General Hospital is the first U.S. site to initiate a pivotal clinical trial of AquaPass, a novel system for fluid overload in heart failure patients.